Fig. 3.
Cumulative incidence of chronic GVHD of 165 patients who received cyclosporine/methotrexate, 49.4% (◊) and 164 patients who received tacrolimus/methotrexate, 55.9% (□); absolute difference = 6.5%, 95% CI = −8.0 to 21.1 (P = .8, Wilcoxon).
Cumulative incidence of chronic GVHD of 165 patients who received cyclosporine/methotrexate, 49.4% (◊) and 164 patients who received tacrolimus/methotrexate, 55.9% (□); absolute difference = 6.5%, 95% CI = −8.0 to 21.1 (P = .8, Wilcoxon).
